Docoh
Loading...

NVS Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Company profile

NVS stock data

(
)

Calendar

26 Jan 21
11 Apr 21
31 Dec 21
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Novartis earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Jul 20 Novartis Pharma Common Stock Conversion Aquire C No No 0 5,908,089 0 5,908,089
14 Jul 20 Novartis Pharma Series C Preferred Stock Common Stock Conversion Dispose C No No 0 7,367,387 0 0
30 Jun 20 Novartis Bioventures Common Stock Buy Aquire P Yes No 17 125,000 2.13M 1,181,258
30 Jun 20 Novartis Bioventures Common Stock Conversion Aquire C Yes No 0 199,996 0 1,056,258
30 Jun 20 Novartis Bioventures Common Stock Conversion Aquire C Yes No 0 856,262 0 856,262
30 Jun 20 Novartis Bioventures Series B Preferred Stock Common Stock Conversion Dispose C Yes No 0 199,996 0 0
30 Jun 20 Novartis Bioventures Series A Preferred Stock Common Stock Conversion Dispose C Yes No 0 856,262 0 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

9.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1112 1064 +4.5%
Opened positions 139 84 +65.5%
Closed positions 91 85 +7.1%
Increased positions 360 327 +10.1%
Reduced positions 408 436 -6.4%
13F shares
Current Prev Q Change
Total value 21.32B 19.84B +7.5%
Total shares 225.86M 224.21M +0.7%
Total puts 1.07M 1.24M -14.1%
Total calls 2.31M 2.03M +13.7%
Total put/call ratio 0.5 0.6 -24.5%
Largest owners
Shares Value Change
Primecap Management 21.81M $2.06B -3.4%
Dodge & Cox 21.62M $2.04B -0.8%
Loomis Sayles & Co L P 20.12M $1.9B +91.5%
BAC Bank Of America 9.81M $926.39M +21.1%
Fisher Asset Management 9.34M $881.77M +3.0%
BEN Franklin Resources 8.52M $804.54M +2.3%
Aristotle Capital Management 7.12M $672.16M +5.3%
Mawer Investment Management 6.63M $625.66M -22.2%
WFC Wells Fargo & Co. 6.35M $599.9M -3.3%
Boston Partners 6.05M $571.41M -3.6%
Largest transactions
Shares Bought/sold Change
Loomis Sayles & Co L P 20.12M +9.61M +91.5%
Renaissance Technologies 4.76M -1.92M -28.8%
Mawer Investment Management 6.63M -1.89M -22.2%
BAC Bank Of America 9.81M +1.71M +21.1%
Arrowstreet Capital, Limited Partnership 4.82K -1.7M -99.7%
UBS UBS Group AG - Registered Shares 5.52M -1.13M -17.0%
Point72 Asset Management 0 -794.93K EXIT
Capital International Investors 0 -780.19K EXIT
Primecap Management 21.81M -765.49K -3.4%
ATAC Neuberger Berman 1.45M -749.62K -34.0%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Abdul, abnormal, abnormally, aboveOverall, aboveThe, accor, addi, ADT, advocacy, advocate, Alnylam, amazing, Amplyx, AMSP, andcorresponding, anddiscussed, andresearch, AndrewsA, annuity, anonymously, antidiabetic, AOSD, Arsenal, ascomycin, asthe, Atectura, attained, attestation, Austrian, autoinjector, baby, benign, bet, BIAC, biannually, Biden, biodiversity, Biome, blockage, Boardp, bribery, broadest, brochure, Burckhardt, caliber, cavity, challengesi, checkpoint, childcare, childhood, choice, cholesterol, cial, colony, comment, CommitteeRISKCommitteeSCIENCE, compensatory, Compression, con, consultantpMeetingsNumber, contextualize, COVID, CRSwNP, CTS, currenciesNo, curtailment, customizable, cycleFor, DARPin, DatarB, deeply, deploy, deploying, developmentse, Dexcom, DFSP, digestive, DirectorsElection, DirectorsVice, discussedthe, dissociation, divergence, DMT, DPA, Egon, ELARA, endo, Enerzair, entrepreneurship, EPM, equating, era, Ernst, ERP, ERT, ESPP, ethnic, ethnicity, EVP, FCPA, FcyR, finan, FRA, frameworki, FudgeB, Fusion, GCSF, Genotropin, geo, gevokizumab, GlaxoSmithKlineNovo, governancei, grateful, gratitude, greatest, groupsMeetingsNumber, guest, GvHD, HCP, HDL, HellerF, HellerW, Helmholtz, HF, HHS, hoc, humanitarian, hybrid, icenticaftor, ICS, IncentiveLTPP, inequality, influential, ini, Inspector, introductory, investmenti, irbesartan, irreversible, issuesp, ity, Jameel, job, JohnsonPfizer, jumpstart, Kellogg, Kenya, Kesimpta, kg, KlingerChief, KPMG, Kymriahand, Lastly, Latif, LDL, leak, Leqvio, lifted, lighthouse, lobbying, lockup, logistical, Lux, Luxembourg, lymph, machine, machinery, macula, maternal, MDS, measuresBalanced, medianTOTAL, membersp, messaging, MetANNUAL, methodology, MetSolid, MF, MFN, millionBelowGroup, mind, MoroneyA, MoroneyC, MPD, multitude, myelin, natriuretic, navigate, navigated, necessity, Nerve, Newman, nimble, Ninety, nonprofit, nonworking, Northwestern, Novartisleadership, NRDL, objectivesMetOverall, occurrence, Officerd, OfficerSteffen, Omnitrope, opportuni, orchestrated, organizationsThe, OS, pandemic, pany, passionate, pen, perspective, PGR, pillarsp, placement, plaintiff, PlantaSCIENCE, portfoliosiMeetingsNumber, Poten, practicesAuditorsAuditor, practicesBoard, predominantly, processp, Proctor, productiv, proposedto, Puller, pump, race, racial, ran, rangeof, readout, rebound, recombinat, Regenerative, restrain, resultseMeetingsNumber, reviewsand, RFS, riskse, River, SABA, sabatolimab, SAPA, Sarl, scientist, scorecardMetTOTAL, seamlessly, Sensoready, Shirley, shortlisted, sincere, slowdown, sMeetingsNumber, societal, solicit, somatropin, spleen, SpotOn, stabilitye, statin, steady, sticky, STO, subtype, swollen, Tabrecta, Tabrectashowed, talking, tampered, Tanzania, targetsp, tech, technologicaland, technologyi, textbook, tial, tinue, tion, tislelizumab, Topco, toUSD, traction, TSLP, unacceptable, unanticipated, unavailability, unclear, uncomplicated, undisrupted, Unfit, unintentional, unusually, upscaling, VBP, VEGF, vertically, veteran, Vietnam, weighed, white, WintersRisk, withthe, workload, worse, writer, youth, Zehnder
Removed: abuse, activating, adipocytic, adult, advertised, akcea, alfaHexal, Allergan, alliance, allogeneic, alteration, Alzheimer, ambulatory, AMG, AML, amlodipine, analytical, Andr, anti, anticipating, antimalarial, antioxidant, antisense, apociii, approvability, artificial, atopic, attack, attractive, Ball, bankruptcy, Banner, Barbera, Barrett, begun, besylate, bioavailable, biotech, blinded, blockbuster, Boundary, branaplam, Brexit, BTK, built, bulk, CA, calcitonin, calcium, capability, Cardiology, Cellular, cenicriviroc, chance, chemotherapy, choroidal, cipargamin, CIU, clearance, clearing, clofazimine, CNV, cognitive, coherence, coinsurance, collectability, Colorado, communicate, compensated, complementary, complemented, confirmed, conflict, continually, controlling, cope, corticosteroid, counter, coupled, crystalline, Cushing, daily, decompensated, deferasirox, delinquency, demographic, dependence, devastating, devoted, diagnose, diagnosed, differentiated, disaster, disrupting, dissolution, disulfide, divestiture, Dublin, easier, economically, eczema, EGFR, elderly, eliminate, embarked, employing, encore, encounter, enforce, enforceable, England, erenumab, everyday, examined, expiring, falciparum, familial, farnesoid, FCT, fever, fewer, FMF, Fort, FortiHFy, fragmented, furoate, FXR, generation, glaucoma, groundwater, harboring, heightening, Hicksville, Histamine, house, humanity, hydrochloride, hyperimmunoglobulin, hypertension, identical, IIa, IIb, IIIb, immunotherapy, indistinguishable, induce, inducing, infarction, infection, ingenuity, inhibit, intelligence, interconnected, interfere, investigated, ipilimumab, IPO, Ireland, Jadenu, Journal, Kuala, lapse, letrozole, ligelizumab, LLC, loading, LogMAR, lubricant, lubricin, lumefantrine, Lumpur, lymphocyte, lymphocytic, Malaysia, mandating, masked, mCRC, Mediterranean, Mexico, MHLW, microsatellite, migraine, minimizing, mismatch, moderate, Modern, momentum, MONALEESA, motivate, MSS, multisystem, muscarinic, Mycobacterial, myeloma, myocardial, myopia, nearby, neonatal, neovascularization, neprilysin, neurohormonal, neuropathic, Nevada, nivolumab, onset, Opdivo, opened, optimization, orally, osilodrostat, output, ovarian, overload, parasite, pathologic, pazopanib, pegfilgrastim, Penn, Perelman, peripheral, Pfizer, pill, pioneer, placebo, plague, play, PMDA, pMMR, potent, Prague, precipitation, prematurity, premenopausal, presbyopia, prevalence, preventive, procedural, proficient, prospective, publicity, pursue, qualification, radical, RCC, reading, ready, recurring, redistribution, rejection, rejuvenate, renewable, replenish, researching, rest, restore, retire, revealed, reversible, revision, rewarding, rigid, rituximab, routinely, Rydapt, sacubitril, safer, Sanitation, sarcoma, scheduled, Schweizerhalle, shorten, signal, simplifying, Slavery, slight, sodium, soft, softening, soil, sophisticated, splicing, standardizing, streamlined, stroke, struggle, subtracted, superiority, supplant, suppressing, sustaining, temperature, thalassemia, tightly, tissue, transactional, transcend, transduction, transferable, transmission, transplant, travoprost, trillion, tropifexor, unexpectedly, universal, unprecedented, uptake, urban, urbanization, vessel, visually, vivax, Watson, weight, widespread, wild, win, worsen, Yervoy, yielding, younger, Ziarco, Zometa